Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Sell
28
SNN Quote, Financials, Valuation and Earnings
Last price:
$25.03
Seasonality move
:
2.6%
Day range:
$23.91 - $25.98
52-week range:
$23.65 - $31.72
Dividend yield:
2.9%
P/E ratio:
27.50x
P/S ratio:
1.95x
P/B ratio:
2.14x
Volume:
1.6M
Avg. volume:
908.5K
1-year change:
4.83%
Market cap:
$11.3B
Revenue:
$5.8B
EPS (TTM):
$0.94
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
SNN
Smith & Nephew PLC
|
$1.4B | -- | -- | -- | $32.14 |
|
ADAP
Adaptimmune Therapeutics PLC
|
$7M | -$0.17 | -92.5% | -8.33% | $1.71 |
|
BCYC
Bicycle Therapeutics PLC
|
$8.7M | -$0.81 | -55.59% | -31.65% | $27.70 |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -- | -- | $17.97 |
|
NCNA
NuCana PLC
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
VRNA
Verona Pharma PLC
|
$53.6M | -$0.03 | -- | -89.84% | $81.00 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
SNN
Smith & Nephew PLC
|
$25.85 | $32.14 | $11.3B | 27.50x | $0.46 | 2.9% | 1.95x |
|
ADAP
Adaptimmune Therapeutics PLC
|
$0.23 | $1.71 | $60M | -- | $0.00 | 0% | 0.33x |
|
BCYC
Bicycle Therapeutics PLC
|
$6.88 | $27.70 | $476.1M | -- | $0.00 | 0% | 11.35x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
$1.51 | $17.97 | $1M | -- | $0.00 | 0% | 1.11x |
|
NCNA
NuCana PLC
|
$0.75 | $104.00 | $4.5M | -- | $0.00 | 0% | -- |
|
VRNA
Verona Pharma PLC
|
$57.91 | $81.00 | $4.9B | -- | $0.00 | 0% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
SNN
Smith & Nephew PLC
|
37.25% | 0.641 | 29.11% | 1.21x |
|
ADAP
Adaptimmune Therapeutics PLC
|
80.92% | 4.133 | 36.44% | 2.60x |
|
BCYC
Bicycle Therapeutics PLC
|
-- | 1.224 | -- | 13.61x |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | 1.825 | -- | 1.20x |
|
NCNA
NuCana PLC
|
-- | 0.371 | -- | -- |
|
VRNA
Verona Pharma PLC
|
37.04% | 0.836 | 3.06% | 10.24x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
SNN
Smith & Nephew PLC
|
-- | -- | 4.91% | 7.88% | -- | -- |
|
ADAP
Adaptimmune Therapeutics PLC
|
-- | -$57.2M | -93.9% | -140.5% | -2197.67% | -$35.4M |
|
BCYC
Bicycle Therapeutics PLC
|
-- | -$67.1M | -25.48% | -26.21% | -1426.21% | -$9.8M |
|
BDRX
Biodexa Pharmaceuticals PLC
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
NCNA
NuCana PLC
|
-- | -$1.6M | -- | -- | -- | -$9.3M |
|
VRNA
Verona Pharma PLC
|
$34.6M | -$17.8M | -60.44% | -88.7% | -41.57% | -$29.4M |
Smith & Nephew PLC vs. Competitors
-
Which has Higher Returns SNN or ADAP?
Adaptimmune Therapeutics PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of -2303.38%. Smith & Nephew PLC's return on equity of 7.88% beat Adaptimmune Therapeutics PLC's return on equity of -140.5%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew PLC-- -- $8.4B ADAPAdaptimmune Therapeutics PLC-- -$0.31 $62.1M -
What do Analysts Say About SNN or ADAP?
Smith & Nephew PLC has a consensus price target of $32.14, signalling upside risk potential of 24.34%. On the other hand Adaptimmune Therapeutics PLC has an analysts' consensus of $1.71 which suggests that it could grow by 631.36%. Given that Adaptimmune Therapeutics PLC has higher upside potential than Smith & Nephew PLC, analysts believe Adaptimmune Therapeutics PLC is more attractive than Smith & Nephew PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew PLC3 2 0 ADAPAdaptimmune Therapeutics PLC2 2 0 -
Is SNN or ADAP More Risky?
Smith & Nephew PLC has a beta of 0.714, which suggesting that the stock is 28.646% less volatile than S&P 500. In comparison Adaptimmune Therapeutics PLC has a beta of 2.845, suggesting its more volatile than the S&P 500 by 184.488%.
-
Which is a Better Dividend Stock SNN or ADAP?
Smith & Nephew PLC has a quarterly dividend of $0.46 per share corresponding to a yield of 2.9%. Adaptimmune Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 79.37% of its earnings as a dividend. Adaptimmune Therapeutics PLC pays out -- of its earnings as a dividend. Smith & Nephew PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or ADAP?
Smith & Nephew PLC quarterly revenues are --, which are smaller than Adaptimmune Therapeutics PLC quarterly revenues of $3.2M. Smith & Nephew PLC's net income of -- is lower than Adaptimmune Therapeutics PLC's net income of -$74.2M. Notably, Smith & Nephew PLC's price-to-earnings ratio is 27.50x while Adaptimmune Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 1.95x versus 0.33x for Adaptimmune Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew PLC1.95x 27.50x -- -- ADAPAdaptimmune Therapeutics PLC0.33x -- $3.2M -$74.2M
-
Which has Higher Returns SNN or BCYC?
Bicycle Therapeutics PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of -1398.44%. Smith & Nephew PLC's return on equity of 7.88% beat Bicycle Therapeutics PLC's return on equity of -26.21%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew PLC-- -- $8.4B BCYCBicycle Therapeutics PLC-- -$0.75 $793.1M -
What do Analysts Say About SNN or BCYC?
Smith & Nephew PLC has a consensus price target of $32.14, signalling upside risk potential of 24.34%. On the other hand Bicycle Therapeutics PLC has an analysts' consensus of $27.70 which suggests that it could grow by 302.62%. Given that Bicycle Therapeutics PLC has higher upside potential than Smith & Nephew PLC, analysts believe Bicycle Therapeutics PLC is more attractive than Smith & Nephew PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew PLC3 2 0 BCYCBicycle Therapeutics PLC4 3 0 -
Is SNN or BCYC More Risky?
Smith & Nephew PLC has a beta of 0.714, which suggesting that the stock is 28.646% less volatile than S&P 500. In comparison Bicycle Therapeutics PLC has a beta of 1.398, suggesting its more volatile than the S&P 500 by 39.825%.
-
Which is a Better Dividend Stock SNN or BCYC?
Smith & Nephew PLC has a quarterly dividend of $0.46 per share corresponding to a yield of 2.9%. Bicycle Therapeutics PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 79.37% of its earnings as a dividend. Bicycle Therapeutics PLC pays out -- of its earnings as a dividend. Smith & Nephew PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or BCYC?
Smith & Nephew PLC quarterly revenues are --, which are smaller than Bicycle Therapeutics PLC quarterly revenues of $3.7M. Smith & Nephew PLC's net income of -- is lower than Bicycle Therapeutics PLC's net income of -$51.9M. Notably, Smith & Nephew PLC's price-to-earnings ratio is 27.50x while Bicycle Therapeutics PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 1.95x versus 11.35x for Bicycle Therapeutics PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew PLC1.95x 27.50x -- -- BCYCBicycle Therapeutics PLC11.35x -- $3.7M -$51.9M
-
Which has Higher Returns SNN or BDRX?
Biodexa Pharmaceuticals PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of --. Smith & Nephew PLC's return on equity of 7.88% beat Biodexa Pharmaceuticals PLC's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew PLC-- -- $8.4B BDRXBiodexa Pharmaceuticals PLC-- -- $6M -
What do Analysts Say About SNN or BDRX?
Smith & Nephew PLC has a consensus price target of $32.14, signalling upside risk potential of 24.34%. On the other hand Biodexa Pharmaceuticals PLC has an analysts' consensus of $17.97 which suggests that it could grow by 1098.12%. Given that Biodexa Pharmaceuticals PLC has higher upside potential than Smith & Nephew PLC, analysts believe Biodexa Pharmaceuticals PLC is more attractive than Smith & Nephew PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew PLC3 2 0 BDRXBiodexa Pharmaceuticals PLC1 0 0 -
Is SNN or BDRX More Risky?
Smith & Nephew PLC has a beta of 0.714, which suggesting that the stock is 28.646% less volatile than S&P 500. In comparison Biodexa Pharmaceuticals PLC has a beta of 1.705, suggesting its more volatile than the S&P 500 by 70.482%.
-
Which is a Better Dividend Stock SNN or BDRX?
Smith & Nephew PLC has a quarterly dividend of $0.46 per share corresponding to a yield of 2.9%. Biodexa Pharmaceuticals PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 79.37% of its earnings as a dividend. Biodexa Pharmaceuticals PLC pays out -- of its earnings as a dividend. Smith & Nephew PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or BDRX?
Smith & Nephew PLC quarterly revenues are --, which are smaller than Biodexa Pharmaceuticals PLC quarterly revenues of --. Smith & Nephew PLC's net income of -- is lower than Biodexa Pharmaceuticals PLC's net income of --. Notably, Smith & Nephew PLC's price-to-earnings ratio is 27.50x while Biodexa Pharmaceuticals PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 1.95x versus 1.11x for Biodexa Pharmaceuticals PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew PLC1.95x 27.50x -- -- BDRXBiodexa Pharmaceuticals PLC1.11x -- -- --
-
Which has Higher Returns SNN or NCNA?
NuCana PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of --. Smith & Nephew PLC's return on equity of 7.88% beat NuCana PLC's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew PLC-- -- $8.4B NCNANuCana PLC-- -$0.32 -- -
What do Analysts Say About SNN or NCNA?
Smith & Nephew PLC has a consensus price target of $32.14, signalling upside risk potential of 24.34%. On the other hand NuCana PLC has an analysts' consensus of $104.00 which suggests that it could grow by 13766.67%. Given that NuCana PLC has higher upside potential than Smith & Nephew PLC, analysts believe NuCana PLC is more attractive than Smith & Nephew PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew PLC3 2 0 NCNANuCana PLC0 1 0 -
Is SNN or NCNA More Risky?
Smith & Nephew PLC has a beta of 0.714, which suggesting that the stock is 28.646% less volatile than S&P 500. In comparison NuCana PLC has a beta of 1.464, suggesting its more volatile than the S&P 500 by 46.355%.
-
Which is a Better Dividend Stock SNN or NCNA?
Smith & Nephew PLC has a quarterly dividend of $0.46 per share corresponding to a yield of 2.9%. NuCana PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 79.37% of its earnings as a dividend. NuCana PLC pays out -- of its earnings as a dividend. Smith & Nephew PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or NCNA?
Smith & Nephew PLC quarterly revenues are --, which are smaller than NuCana PLC quarterly revenues of --. Smith & Nephew PLC's net income of -- is lower than NuCana PLC's net income of -$836.1K. Notably, Smith & Nephew PLC's price-to-earnings ratio is 27.50x while NuCana PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 1.95x versus -- for NuCana PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew PLC1.95x 27.50x -- -- NCNANuCana PLC-- -- -- -$836.1K
-
Which has Higher Returns SNN or VRNA?
Verona Pharma PLC has a net margin of -- compared to Smith & Nephew PLC's net margin of -92.29%. Smith & Nephew PLC's return on equity of 7.88% beat Verona Pharma PLC's return on equity of -88.7%.
Company Gross Margin Earnings Per Share Invested Capital SNNSmith & Nephew PLC-- -- $8.4B VRNAVerona Pharma PLC94.44% -$0.40 $324.9M -
What do Analysts Say About SNN or VRNA?
Smith & Nephew PLC has a consensus price target of $32.14, signalling upside risk potential of 24.34%. On the other hand Verona Pharma PLC has an analysts' consensus of $81.00 which suggests that it could grow by 39.87%. Given that Verona Pharma PLC has higher upside potential than Smith & Nephew PLC, analysts believe Verona Pharma PLC is more attractive than Smith & Nephew PLC.
Company Buy Ratings Hold Ratings Sell Ratings SNNSmith & Nephew PLC3 2 0 VRNAVerona Pharma PLC5 0 0 -
Is SNN or VRNA More Risky?
Smith & Nephew PLC has a beta of 0.714, which suggesting that the stock is 28.646% less volatile than S&P 500. In comparison Verona Pharma PLC has a beta of 0.165, suggesting its less volatile than the S&P 500 by 83.527%.
-
Which is a Better Dividend Stock SNN or VRNA?
Smith & Nephew PLC has a quarterly dividend of $0.46 per share corresponding to a yield of 2.9%. Verona Pharma PLC offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Smith & Nephew PLC pays 79.37% of its earnings as a dividend. Verona Pharma PLC pays out -- of its earnings as a dividend. Smith & Nephew PLC's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios SNN or VRNA?
Smith & Nephew PLC quarterly revenues are --, which are smaller than Verona Pharma PLC quarterly revenues of $36.7M. Smith & Nephew PLC's net income of -- is lower than Verona Pharma PLC's net income of -$33.8M. Notably, Smith & Nephew PLC's price-to-earnings ratio is 27.50x while Verona Pharma PLC's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Smith & Nephew PLC is 1.95x versus -- for Verona Pharma PLC. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income SNNSmith & Nephew PLC1.95x 27.50x -- -- VRNAVerona Pharma PLC-- -- $36.7M -$33.8M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Archer Aviation a Buy, Sell or Hold?
Vertical takeoff and landing (eVTOL) aircraft sound futuristic but that’s…
Down 50%, Is Dell Technologies a Buy?
Dell (NYSE:DELL)’s share price has been on a roller coaster…
Stock Ideas
Sell
43
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Alerts
Sell
33
BULZ alert for Apr 10
MicroSectors Solactive FANG & Innov 3X Levd ETN [BULZ] is down 15.35% over the past day.
Sell
31
TECS alert for Apr 10
Direxion Daily Technology Bear 3x Shares [TECS] is up 12.66% over the past day.
Sell
48
FNGA alert for Apr 10
MicroSectors FANG+ Index 3X Leveraged ETN [FNGA] is down 13.3% over the past day.
